Literature DB >> 10805798

Long-term kinetics of T cell production in HIV-infected subjects treated with highly active antiretroviral therapy.

S Fleury1, G P Rizzardi, A Chapuis, G Tambussi, C Knabenhans, E Simeoni, J Y Meuwly, J M Corpataux, A Lazzarin, F Miedema, G Pantaleo.   

Abstract

The long-term kinetics of T cell production following highly active antiretroviral therapy (HAART) were investigated in blood and lymph node in a group of HIV-infected subjects at early stage of established infection and prospectively studied for 72 wk. Before HAART, CD4 and CD8 T cell turnover was increased. However, the total number of proliferating CD4(+) T lymphocytes, i.e., CD4(+)Ki67(+) T lymphocytes, was not significantly different in HIV-infected (n = 73) and HIV-negative (n = 15) subjects, whereas proliferating CD8(+)Ki67(+) T lymphocytes were significantly higher in HIV-infected subjects. After HAART, the total body number of proliferating CD4(+)Ki67(+) T lymphocytes increased over time and was associated with an increase of both naive and memory CD4(+) T cells. The maximal increase (2-fold) was observed at week 36, whereas at week 72 the number of proliferating CD4(+) T cells dropped to baseline levels, i.e., before HAART. The kinetics of the fraction of proliferating CD4 and CD8 T cells were significantly correlated with the changes in the total body number of these T cell subsets. These results demonstrate a direct relationship between ex vivo measures of T cell production and quantitative changes in total body T lymphocyte populations. This study provides advances in the delineation of the kinetics of T cell production in HIV infection in the presence and/or in the absence of HAART.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10805798      PMCID: PMC25839          DOI: 10.1073/pnas.97.10.5393

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  40 in total

1.  Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease.

Authors:  B Autran; G Carcelain; T S Li; C Blanc; D Mathez; R Tubiana; C Katlama; P Debré; J Leibowitch
Journal:  Science       Date:  1997-07-04       Impact factor: 47.728

Review 2.  T cell turnover in HIV-1 disease.

Authors:  M K Hellerstein; J M McCune
Journal:  Immunity       Date:  1997-11       Impact factor: 31.745

3.  HIV-1 Vpr increases viral expression by manipulation of the cell cycle: a mechanism for selection of Vpr in vivo.

Authors:  W C Goh; M E Rogel; C M Kinsey; S F Michael; P N Fultz; M A Nowak; B H Hahn; M Emerman
Journal:  Nat Med       Date:  1998-01       Impact factor: 53.440

4.  Rapid turnover of T lymphocytes in SIV-infected rhesus macaques.

Authors:  H Mohri; S Bonhoeffer; S Monard; A S Perelson; D D Ho
Journal:  Science       Date:  1998-02-20       Impact factor: 47.728

5.  Vigorous HIV-1-specific CD4+ T cell responses associated with control of viremia.

Authors:  E S Rosenberg; J M Billingsley; A M Caliendo; S L Boswell; P E Sax; S A Kalams; B D Walker
Journal:  Science       Date:  1997-11-21       Impact factor: 47.728

6.  Counting antigen-specific CD8 T cells: a reevaluation of bystander activation during viral infection.

Authors:  K Murali-Krishna; J D Altman; M Suresh; D J Sourdive; A J Zajac; J D Miller; J Slansky; R Ahmed
Journal:  Immunity       Date:  1998-02       Impact factor: 31.745

7.  Turnover of CD4+ and CD8+ T lymphocytes in HIV-1 infection as measured by Ki-67 antigen.

Authors:  N Sachsenberg; A S Perelson; S Yerly; G A Schockmel; D Leduc; B Hirschel; L Perrin
Journal:  J Exp Med       Date:  1998-04-20       Impact factor: 14.307

8.  Quantitation of HIV-1-specific cytotoxic T lymphocytes and plasma load of viral RNA.

Authors:  G S Ogg; X Jin; S Bonhoeffer; P R Dunbar; M A Nowak; S Monard; J P Segal; Y Cao; S L Rowland-Jones; V Cerundolo; A Hurley; M Markowitz; D D Ho; D F Nixon; A J McMichael
Journal:  Science       Date:  1998-03-27       Impact factor: 47.728

9.  Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy.

Authors:  R M Gulick; J W Mellors; D Havlir; J J Eron; C Gonzalez; D McMahon; D D Richman; F T Valentine; L Jonas; A Meibohm; E A Emini; J A Chodakewitz
Journal:  N Engl J Med       Date:  1997-09-11       Impact factor: 91.245

10.  Maintenance antiretroviral therapies in HIV-infected subjects with undetectable plasma HIV RNA after triple-drug therapy. AIDS Clinical Trials Group Study 343 Team.

Authors:  D V Havlir; I C Marschner; M S Hirsch; A C Collier; P Tebas; R L Bassett; J P Ioannidis; M K Holohan; R Leavitt; G Boone; D D Richman
Journal:  N Engl J Med       Date:  1998-10-29       Impact factor: 91.245

View more
  25 in total

1.  Increased turnover of T lymphocytes in HIV-1 infection and its reduction by antiretroviral therapy.

Authors:  H Mohri; A S Perelson; K Tung; R M Ribeiro; B Ramratnam; M Markowitz; R Kost; A Hurley; L Weinberger; D Cesar; M K Hellerstein; D D Ho
Journal:  J Exp Med       Date:  2001-11-05       Impact factor: 14.307

2.  Impact of HIV-1 infection and highly active antiretroviral therapy on the kinetics of CD4+ and CD8+ T cell turnover in HIV-infected patients.

Authors:  R A Lempicki; J A Kovacs; M W Baseler; J W Adelsberger; R L Dewar; V Natarajan; M C Bosche; J A Metcalf; R A Stevens; L A Lambert; W G Alvord; M A Polis; R T Davey; D S Dimitrov; H C Lane
Journal:  Proc Natl Acad Sci U S A       Date:  2000-12-05       Impact factor: 11.205

3.  Peptide modulators of Src activity in G1 regulate entry into S phase and proliferation of NIH 3T3 cells.

Authors:  Vidya Mamidipudi; Laura D Miller; Daria Mochly-Rosen; Christine A Cartwright
Journal:  Biochem Biophys Res Commun       Date:  2006-11-15       Impact factor: 3.575

4.  Thymic function-related markers within the thymus and peripheral blood: Are they comparable?

Authors:  María Victoria Arellano; Antonio Ordóñez; Ezequiel Ruiz-Mateos; Santiago R Leal-Noval; Sonia Molina-Pinelo; Ana Hernández; Alejandro Vallejo; Rafael Hinojosa; Manuel Leal
Journal:  J Clin Immunol       Date:  2006-01       Impact factor: 8.317

5.  Differential effects of HIV viral load and CD4 count on proliferation of naive and memory CD4 and CD8 T lymphocytes.

Authors:  Sharat Srinivasula; Richard A Lempicki; Joseph W Adelsberger; Chiung-Yu Huang; Joshua Roark; Philip I Lee; Adam Rupert; Randy Stevens; Irini Sereti; H Clifford Lane; Michele Di Mascio; Joseph A Kovacs
Journal:  Blood       Date:  2011-05-11       Impact factor: 22.113

6.  Mechanisms of gastrointestinal CD4+ T-cell depletion during acute and early human immunodeficiency virus type 1 infection.

Authors:  Saurabh Mehandru; Michael A Poles; Klara Tenner-Racz; Victoria Manuelli; Patrick Jean-Pierre; Peter Lopez; Anita Shet; Andrea Low; Hiroshi Mohri; Daniel Boden; Paul Racz; Martin Markowitz
Journal:  J Virol       Date:  2006-10-25       Impact factor: 5.103

Review 7.  2019 European Thyroid Association Guidelines on the Management of Thyroid Dysfunction following Immune Reconstitution Therapy.

Authors:  Ilaria Muller; Carla Moran; Beatriz Lecumberri; Brigitte Decallonne; Neil Robertson; Joanne Jones; Colin M Dayan
Journal:  Eur Thyroid J       Date:  2019-07-04

8.  Naïve T-cell dynamics in human immunodeficiency virus type 1 infection: effects of highly active antiretroviral therapy provide insights into the mechanisms of naive T-cell depletion.

Authors:  Michele Di Mascio; Irini Sereti; Lynn T Matthews; Ven Natarajan; Joseph Adelsberger; Richard Lempicki; Christian Yoder; Elizabeth Jones; Catherine Chow; Julia A Metcalf; Igor A Sidorov; Dimiter S Dimitrov; Michael A Polis; Joseph A Kovacs
Journal:  J Virol       Date:  2006-03       Impact factor: 5.103

9.  HIV-1-specific CD4+ T lymphocyte turnover and activation increase upon viral rebound.

Authors:  Thomas J Scriba; Hua-Tang Zhang; Helen L Brown; Annette Oxenius; Norbert Tamm; Sarah Fidler; Julie Fox; Jonathan N Weber; Paul Klenerman; Cheryl L Day; Michaela Lucas; Rodney E Phillips
Journal:  J Clin Invest       Date:  2005-02       Impact factor: 14.808

10.  Cancer Risk in Older Persons Living With Human Immunodeficiency Virus Infection in the United States.

Authors:  Parag Mahale; Eric A Engels; Anna E Coghill; Amy R Kahn; Meredith S Shiels
Journal:  Clin Infect Dis       Date:  2018-06-18       Impact factor: 9.079

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.